Publications







Evaluation of Functional Marrow Irradiation Based on Skeletal Marrow Composition Obtained Using Dual-Energy Computed Tomography.
Int J Radiat Oncol Biol Phys 2016 Nov 6;96(3):679-87. Epub 2016 Jul 6.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Department of Therapeutic Radiology, University of Minnesota, Minneapolis, Minnesota; Department of Radiation Oncology, Beckman Research Institute, City of Hope, Duarte, California. Electronic address:



Umbilical cord blood transplantation is a suitable option for consolidation of acute myeloid leukemia with FLT3-ITD.
Haematologica 2016 Aug 28;101(8):e348-51. Epub 2016 Apr 28.
Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA



Loss of T Follicular Helper Cells in the Peripheral Blood of Patients with Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant 2016 May 13;22(5):825-33. Epub 2016 Jan 13.
Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minnesota. Electronic address:










An exploratory analysis of mitochondrial haplotypes and allogeneic hematopoietic cell transplantation outcomes.
Biol Blood Marrow Transplant 2015 Jan 6;21(1):81-8. Epub 2014 Oct 6.
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota; Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota.


One-unit versus two-unit cord-blood transplantation for hematologic cancers.
N Engl J Med 2014 Oct;371(18):1685-94
From the University of Minnesota Medical School, Minneapolis (J.E.W., M.R.V.); Medical College of Wisconsin, Milwaukee (M.E., D.M., M.M.H.); EMMES Corporation, Rockville, MD (S.C., Y.W.); BC Children's Hospital, Vancouver (K.R.S.), and University of Manitoba, Winnipeg (D.A.W.) - both in Canada; Children's Hospital of Philadelphia, Philadelphia (N.B.); Fred Hutchinson Cancer Research Center, Seattle (C.D.); Indiana University, Indianapolis (P.H.); University of Michigan, Ann Arbor (E.P.); University of California San Francisco Benioff Children's Hospital Oakland, Oakland (M.W.); and Duke University, Durham, NC (J.K.).





Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Clin Cancer Res 2013 Jul 20;19(14):3844-55. Epub 2013 May 20.
Division of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.
Cancer Biother Radiopharm 2013 May 23;28(4):274-82. Epub 2013 Apr 23.
1 Section of Molecular Cancer Therapeutics, Therapeutic Radiology-Radiation Oncology, University of Minnesota Masonic Cancer Center , Minneapolis, Minnesota.

A randomized trial of one versus two doses of influenza vaccine after allogeneic transplantation.
Biol Blood Marrow Transplant 2013 Jan 29;19(1):109-16. Epub 2012 Aug 29.
Division of Hematology/Oncology and Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA.

Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant 2013 Jan 6;19(1):138-42. Epub 2012 Sep 6.
Division of Pediatric Hematology-Oncology, University of Minnesota, Amplatz Children's Hospital, Minneapolis, Minnesota 55455, USA.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Mol Cancer Ther 2012 Dec 17;11(12):2674-84. Epub 2012 Oct 17.
Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, USA.

Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival.
Biol Blood Marrow Transplant 2012 Jun 16;18(6):963-8. Epub 2012 Mar 16.
Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

Natural killer cell differentiation from hematopoietic stem cells: a comparative analysis of heparin- and stromal cell-supported methods.
Biol Blood Marrow Transplant 2012 Apr 7;18(4):536-45. Epub 2011 Dec 7.
Department of Pediatrics, Division of Blood and Marrow Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.

Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.
Biol Blood Marrow Transplant 2012 Mar 10;18(3):480-6. Epub 2011 Dec 10.
Bone Marrow Transplantation Program, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA.



Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies.
Biol Blood Marrow Transplant 2011 Jun 8;17(6):831-40. Epub 2010 Sep 8.
Division of Hematology/Oncology and Blood and Marrow Transplantation in the Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.


Natural killer cell killing of acute myelogenous leukemia and acute lymphoblastic leukemia blasts by killer cell immunoglobulin-like receptor-negative natural killer cells after NKG2A and LIR-1 blockade.
Biol Blood Marrow Transplant 2010 May 6;16(5):612-21. Epub 2010 Feb 6.
Division of Adult Hematology, Oncology and Transplantation, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA.


Hematopoietic cell transplantation for children with acute lymphoblastic leukemia in second complete remission: similar outcomes in recipients of unrelated marrow and umbilical cord blood versus marrow from HLA matched sibling donors.
Biol Blood Marrow Transplant 2009 Sep;15(9):1086-93
Division of Pediatric Hematology/Oncology/Blood and Marrow Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.



Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
N Engl J Med 2017 02;376(6):536-547
From the Department of Medical Oncology, Division of Hematological Malignancies (R.C.L., C.C., J.H.A.), and the Departments of Pediatric Oncology (B.G.M.) and Biostatistics and Computational Biology (R.R., D.N.), Dana-Farber Cancer Institute, and the Division of Hematology, Brigham and Women's Hospital, Harvard Medical School (P.V.G., B.L.E.) - all in Boston; the Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee (W.S., T.W., Z.-H.H., S.J.L.); the Center for International Blood and Marrow Transplant Research, National Marrow Donor Program-Be the Match (M.D.H., S.R.S.), and the Pediatric Blood and Marrow Transplantation Center, University of Minnesota (M.R.V.) - both in Minneapolis; the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle (S.J.L.); Memorial Sloan Kettering Cancer Center, New York (K.H.); and the Institute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany (K.F.).

OF